A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland. Swiss Medical Weekly, [S. l.], v. 155, n. 1, p. 3777, 2025. DOI: 10.57187/s.3777. Disponível em: https://www.smw.ch/index.php/smw/article/view/3777. Acesso em: 23 oct. 2025.